Antibodies from chicken eggs become focus
Biotech company IRI Separation Technologies (IRI) has signed a
distribution agreement to allow the firm to fully focus on the extraction of
antibodies from eggs.
Two major operations are run by the company, namely an egg-breaking
facility where eggs are washed and separated for regular distribution as a
bakery ingredient, and a separation facility where antibodies are extracted from
Vanderpol's Eggs Ltd (VEL) is now in a new distribution agreement with the
company to take over distribution and sale of all liquid and frozen egg products
from its Airdrie egg-breaking facility.
This will allow IRI to focus on its separation operations, which is the
core part of its business. The company, which specialises in the extraction of
polyclonal immunoglobulin antibodies, said it will continue to use egg yolk from
its egg breaking facility, which will be transferred to the company's separation
plant for extraction. These antibodies that are derived from the chicken eggs
are intended for use as a nutraceutical for human consumption.
Immunoglobulins (Ig) are powerful antibodies produced in healthy humans and
other animals to fight infections and prevent disease. Immunoglobulin G (IgG)
accounts for 75% of the total immunoglobulin found in the plasma of healthy
individuals. However, another class of immunoglobulin - IgY - is found in egg
yolks and is the functional equivalent of IgG.
The company intends to market the ingredient for use in foods - initially
as a yolk protein isolate. It ultimately plans to take it to natural health
products that can make health claims, but said that it will take some time to
receive necessary regulatory approvals.
To comment, login here
Or register to be able to comment.